FDCP
ROIV icon

Foster Dykema Cabot & Partners’s Roivant Sciences ROIV Stock Holding History

Foster Dykema Cabot & Partners’s Portfolio ROIV Stock Details ROIV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-72
Closed -$831 – 462
2024
Q3 		$831 Buy
+72
New +$820 ﹤0.01% 478

Other funds holding ROIV

QF
QVT Financial New York $1.37B AUM 148.1% 1-Year Est. Return
SIAU
SB Investment Advisers (UK) London, United Kingdom $7.73B AUM 2.35% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
PSC
Patient Square Capital Menlo Park, California $564M AUM 261.3% 1-Year Est. Return

Foster Dykema Cabot & Partners's ROIV Position: Q4 2024 in Review

Foster Dykema Cabot & Partners sold out of Roivant Sciences (ROIV) in Q4 2024, closing a stake of 72 shares — an estimated $831 sold.

Foster Dykema Cabot & Partners first reported a position in ROIV in Q3 2024 and held it in 1 quarter. The position peaked at $831 in Q3 2024. 318 funds tracked by Wall St. Rank hold ROIV as of Q4 2024.

  • Foster Dykema Cabot & Partners reported no remaining Roivant Sciences position as of Q4 2024 after selling out during the quarter.
  • Foster Dykema Cabot & Partners sold 72 Roivant Sciences shares in Q4 2024, an estimated $831.
  • Foster Dykema Cabot & Partners first reported a position in Roivant Sciences in Q3 2024 and held it in 1 quarter.
  • Foster Dykema Cabot & Partners's Roivant Sciences position peaked at $831 in Q3 2024.
  • 318 funds tracked by Wall St. Rank held Roivant Sciences as of Q4 2024.

Based on Foster Dykema Cabot & Partners's 13F filing for Q4 2024, filed 13 Feb 2025.